 |
BOARD OF DIRECTORS
"We are very pleased to have on our Board the distinguished leaders of these, the most prestigious, Pacific Northwest Health Care Institutions."
-- Dave Sabey
Chairman of the Board
David A. Sabey, Chairman of the Board (President, Sabey Corporation)
| |
 |
|
Born and raised in Washington State, Dave has spent the past 40 years building a successful real estate development company specializing in data centers, health care, office structures and the redevelopment of historic Pacific Northwest buildings. From his earliest experiences developing projects for leading technology companies, Dave has become keenly aware of the impact of digitization on nearly every aspect of our lives and, not least, as a key driver of innovation and our economy.
Accordingly, Dave recently established the Seattle Science Foundation to support the collaboration of medical scientists, practitioners, and engineers and to share the world's most sophisticated skill sets through high bandwidth transmissions. Through SSF and through his collaboration with some of medical technology's most creative and productive thought leaders, Dave is helping to advance a global healthcare network with Seattle as a central node.
Dave and his wife, Sandy, have three children, two of whom work in the family business.
About Sabey Corporation
Sabey Corporation is a privately held company specializing in data centers, medical technology and unique real estate redevelopment projects. Sabey is a leader in the operation of data centers in the Northwest with 1.7 million square feet of mission critical space occupied by government, universities and leading corporations. The firm has received acclaim for its innovative redevelopment of the James Tower Life Sciences Community building at Swedish Medical Center's Cherry Hill Campus in Seattle.
Affiliations
• Trustee Emeritus, Gonzaga University
• Board of Trustees, Seattle University
• President's Council, Eastern Washington University
• Business Advisory Council, University of Notre Dame
• Board of Directors, Institute for Systems Biology
• President's Club, University of Washington
• Advisory Board, Global Health Nexus, Seattle
• Board of Directors, Eastside Catholic High School Foundation
• Alumnus, Young Presidents' Organization
Education
• U.S. Air Force Academy Prep School
• University of Washington
• Eastern Washington University, BA Education
Honors
• Honorary Doctorate of Law, Gonzaga Universityy
|
Mark Reisman, M.D., Board President (Swedish Medical Center & UW)
| |
 |
|
Mark Reisman, M.D., is an interventional cardiologist with the Swedish Heart & Vascular Institute (SHVI). He is director of the medical center's Cardiovascular Research & Education program and Cardiac Catheterization Lab on Swedish's First Hill Campus.
Since joining Swedish's medical staff in 1995, Dr. Reisman has been the site principal investigator on more than 50 clinical trials. In addition, he has been a national Principal Investigator on several trials involving emerging technologies and innovations in neurovascular as well as the structural heart disease area.
Beside his roles at Swedish, Dr. Reisman has been a clinical assistant professor of medicine at the University of Washington since 1995.
|
Patty Sewell, Board Treasurer (Sabey Corporation)
| |
 |
|
Patty joined Sabey Corporation in 1996 as Controller, bringing more than ten years of accounting and administrative management experience. Appointed to her present position in 2003, Patty is primarily responsible for corporate and mortgage financing, risk management, corporate operations, financial reporting and management of accounting operations. She is not only active in helping Sabey obtain its financial objectives, she is passionate about upholding the companys core values. Patty is diligent in setting the internal performance bar high, aspiring to put the Companys best foot forward at all times, earning the affectionate nickname, Patty Perfect from her colleagues. Patty and her staff are committed to bringing the highest level of integrity and customer service to Sabey's business relationships.
|
Arlan Collins, (CollinsWoerman)
| |
 |
|
Arlan Collins has twenty-eight years of experience managing projects for leading Northwest organizations and agencies, the last eighteen as a partner of CollinsWoerman, an architecture, planning and design firm located in downtown Seattle. Since serving as project manager for the design and construction of one of Seattle's first biotech manufacturing facilities, Genetic Systems, Arlan's career has developed alongside the science and technology industry in the Pacific Northwest. He is recognized within the region's construction industry as a leader in promoting the integration of design and construction services.
A registered architect in Washington, Idaho, California and Utah, Arlan earned his bachelor of architecture degree from the University of Idaho in 1978. He is a member of the Board of Directors for both the Bellevue Chamber of Commerce and the Bellevue Downtown Association and recently received the Place Maker of the Year Award for the Bellevue Downtown Plan.
|
Leroy Hood, Ph.D., (Integrated Diagnostics)
| |
 |
|
Dr. Hood's research has focused on fundamental biology (immunity, evolution, genomics) and on bringing engineering to biology through the development of five instruments; the DNA and protein sequencers and synthesizers and the ink-jet oligonucleotide synthesizer (making DNA arrays) for deciphering the various types of biological information (DNA, RNA, proteins and systems). In particular, the DNA sequencer has revolutionized genomics by allowing the rapid automated sequencing of DNA, which played a crucial role in contributing to the successful mapping of the human genome during the 1990s and early 2000s. These instruments constitute the technological foundation for modern molecular biology and genomics. He has applied these technologies to diverse fields including immunology, neurobiology, cancer biology, molecular evolution and systems medicine.
Early in his career, he applied these technologies to the study of molecular immunology (and discovered many of the fundamental mechanisms for antibody diversity) and neurobiology (he cured the first neurological disease by gene transfer in mice). In the late 1980s he realized that to really understand immunology, it would require a systems approach, thus, he began thinking about systems biology.
In 1992, Dr. Hood moved to the University of Washington as founder and Chairman of the cross-disciplinary Department of Molecular Biotechnology (MBT) and developed the ink-jet oligonucleotide synthesizer which synthesized DNA chips. At MBT he initiated systems' studies on cancer biology and prion disease. In 2000, he co-founded the Institute for Systems Biology in Seattle, Washington, to more effectively continue pioneering systems approaches to biology and medicine. Here he has contributed seminal papers to delineating the systems approach to biology and disease and to pioneer developing new technologies (microfluidics/nanotechnology and molecular imaging) in collaboration with colleagues at Caltech. Dr. Hood is now pioneering the idea that the systems approach to disease, the emerging technologies, and powerful new computational and mathematical tools will move medicine from its current reactive mode to a predictive, preventive, personalized and participatory mode (P4 medicine) over the next 5-20 years.
Dr. Hood was awarded the Lasker Prize in 1987 for his studies on the mechanism of immune diversity. Dr. Hood was also awarded the 2002 Kyoto Prize in Advanced Technology for the development of the five different instruments. He received the 2003 Lemelson-MIT Prize for Innovation and Invention for the development of the DNA sequencer. Most recently, Dr. Hood's lifelong contributions to biotechnology have earned him the prestigious 2004 Biotechnology Heritage Award, as well as the 2003 Association for Molecular Pathology (AMP) Award for Excellence in Molecular Diagnostics for his pioneering efforts in molecular diagnostics. In 2006 he received the Heinz Award in Technology, the Economy and Employment, for his extraordinary breakthroughs in biomedical science at the genetic level. In 2007 he was elected to the Inventors Hall of Fame (for the automated DNA sequencer) and in 2008 he received the Pittcon Heritage Award for helping to transform the biotech industry. Dr. Hood has received 17 honorary degrees from Institutions such as Johns Hopkins, Yale, UCLA, and Whitman College. He has published more than 650 peer-reviewed papers, received 15 patents, and has co-authored textbooks in biochemistry, immunology, molecular biology, and genetics, and is just finishing a textbook on systems biology. In addition, he coauthored with Dan Keveles a popular book on the human genome project-The Code of Codes.
Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. Indeed, Dr. Hood is one of only 7 (of more than 6000 members) scientists elected to all three academies (NAS, NAE and IOM). Dr. Hood has also played a role in founding more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. He is currently pioneering systems medicine and the systems approach to disease and has recently cofounded the company Integrated Diagnostics-that hopefully will become a platform company for P4 medicine.
Dr. Hood has had a life-long commitment to K-12 science education and has a major effort at ISB in this regard. Dr. Hood enjoys reading, mountaineering, cross-country skiing, sea kayaking and exercise.
|
Glenn Kawasaki, Ph.D., (President, Carepeutics, Inc.)
| |
 |
|
Dr. Kawasaki is an entrepreneur and a founder of biotechnology companies. He has a Ph.D. in genetics (1979), an MBA (1986), and a law degree (1995) each from the University of Washington (Seattle). He was a research fellow at Harvard Medical School (1979-81). Dr. Kawasaki became the first scientist in 1981 and later the chair of the Science Board at ZymoGenetics, Inc., a Seattle biotech company (ZGEN) that went public in 2002. He has 14 U.S. patents on molecular biology methods for therapeutic and diagnostic products and has hundreds of foreign related patents. His undergraduate degrees in zoology (B.S.) and genetics (A.B.) are from the University of California, Berkeley (1974).
In 1989 Dr. Kawasaki founded Aptein, Inc. and served as CEO, president, and research director of the Seattle company. At Aptein, he created a technology now known as "ribosome display," which is used to engineer human antibodies and other proteins with cell-free methods. In July 1998 Aptein was sold to Cambridge Antibody Technology (CAT) for nine percent of the total shares in the British company. In 2006 AstraZeneca purchased CAT.
In February 1999 he founded Catch Incorporated, a Seattle-area diagnostics firm that has developed a test for homocysteine in human blood. Homocysteine is an amino acid linked to Alzheimer’s Disease, cardiovascular diseases, fetal neural tube defects, osteoporosis, glaucoma, and other illnesses. Dr. Kawasaki is the president and a corporate director of Catch Inc., which is based on his invention.
Dr. Kawasaki is a founder and Board member of Sound Pharmaceuticals Inc., another Seattle start-up (2001), which is focused on preventing and restoring hearing loss. In 2005 he joined Accium BioSciences as the CEO and a director. This company provides contract research services to the pharmaceutical industry for studying drug candidates in humans before Phase I clinical trials. In 2009 Dr. Kawasaki founded Carepeutics, Inc., which is a spin-off of Accium, and serves as the president of this Seattle firm. Carepeutics is a personalized medicine company that uses accelerator mass spectrometry to quantify the distribution into tumors of one or more drugs in humans to predict which combinations are most likely to be effective.
Since 2000, he has been a trustee of the Pacific Northwest Ballet and has been the vice president and chair of the New Work Initiative for this dance company. He served as a trustee and officer of Seattle Children’s Theatre from 2004 to 2007. In 2007 Dr. Kawasaki became a trustee for Seattle Dance Project and is the vice president. In 2009 he became a founding trustee of Whim W’Him, another Seattle dance company.
|
Dave King, (CEO, Laboratory Corporation of America)
Chris Rivera, (WBBA)
| |
 |
|
Chris E. Rivera joined the WBBA as President in 2009, bringing more more than two decades of commercial, licensing and general management experience in the biopharmaceutical industry. Rivera is dedicated to seeing the life sciences industry thrive while creating new jobs and companies. Rivera was the founder and CEO of Hyperion Therapeutics, a specialty biopharmaceutical company focused in the development and commercialization of therapies for gastroenterology and hepatology diseases. Prior to starting Hyperion, he was Senior Vice President of Commercial Operations at Tercica, Inc., where he was responsible for developing and overseeing Tercica's global commercialization strategies and was intimately involved in the development and consummation of an international cross-licensing collaboration with Ipsen. As Senior Vice President of Genzyme Therapeutics, Rivera was largely responsible for building the company's U.S. renal division and assisted in the launch of Renagel® (sevelamer hydrochloride) globally. Earlier in his career, he helped build the initial commercial organizations at Centocor and Cephalon. A Washington state resident since 1985, Rivera holds a Master of Science degree in Audiology from the University of Oklahoma Health Sciences Center; a Bachelor of Science degree in Business from Northwestern Oklahoma State University; and studied Marketing and Management at the Albers Graduate School of Business and Economics at Seattle University.
|
|
